Repligen Considers Acquiring Maravai LifeSciences to Expand Drug-Manufacturing Portfolio

Repligen has approached Maravai LifeSciences Holdings with an acquisition offer. Maravai, valued at $2.5 billion, has struggled since the pandemic subsided. The acquisition is uncertain, and Repligen might sell some of Maravai's divisions. Maravai's stock surged, while Repligen's fell on the news. Discussions with private equity firms are ongoing.

Repligen, a provider of drug manufacturing equipment, has made a potential acquisition offer to Maravai LifeSciences Holdings, known for its vaccine capping reagents. The move occurs amidst Maravai's struggle to diversify following a significant market value drop. The outcome of the offer remains uncertain.

Discussions with private equity firms, including EQT AB, are underway regarding the possible divestiture of Maravai's nucleic acid production unit. Both Repligen and Maravai have not commented on the matter. Maravai's stock saw a significant uptick, contrasting Repligen's share value dip.

Previously, Maravai turned down similar acquisition proposals. The company, established during the COVID-19 vaccine surge, has faced challenges in maintaining its market position post-pandemic. Repligen, founded in 1981, continues to specialize in drug manufacturing efficiency tools, serving major global drug developers and CDMOs.